Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Ophthalmol ; 16: 1245-1254, 2022.
Article in English | MEDLINE | ID: mdl-35493972

ABSTRACT

Purpose: To evaluate the influences and risk factors for severe bleeding complications during glaucoma surgery, and to investigate the role of antiplatelet (AP) and anticoagulant (AC) agents. Methods: This prospective study enrolled patients undergoing trabeculectomy, trabeculotomy (with Trabectome® or Kahook Dual Blade®), viscocanaloplasty and Ahmed or Baerveldt implants. Bleeding severity was graded on an ordinal scale ranging from 0 to 5. Immediately after surgery and one day later, the incidence and severity of bleeding events was documented on a standardized form. A grade ≥3 was defined as severe bleeding. The influence of known systemic disorders, the type of anesthesia, surgical procedure, intraoperative blood pressure, and the use of or change in AP or AC agents on intraoperative bleeding were analyzed. Results: Data from 89 eyes undergoing glaucoma procedures were included (age 71.3y ± 10.5). We observed severe intraoperative bleeding in 8 eyes (9%) and found that concomitant diseases such as the history of a deep vein thrombosis or peripheral arterial occlusive disease, and the type of surgical procedure (trabeculectomy and viscocanaloplasty) were significantly associated with severe bleeding events. By contrast, the use of AP/ AC agents had no significant influence on severe intraoperative bleeding events. Conclusion: According to the results of our study cohort, glaucoma procedures entailing scleral manipulations (trabeculectomy and viscocanaloplasty) and concomitant diseases such as the history of a deep vein thrombosis or peripheral arterial occlusive disease influence the risk of severe intraoperative bleeding events, we detected no increased risk related to concomitant antiplatelet and/ or anticoagulant medication use.

2.
Ophthalmol Retina ; 5(8): e23-e29, 2021 08.
Article in English | MEDLINE | ID: mdl-33915331

ABSTRACT

PURPOSE: To evaluate the influences and risk factors for severe bleeding complications during vitreoretinal surgery and to investigate the role of antiplatelet and anticoagulant agents. DESIGN: Prospective trial. PARTICIPANTS: Patients undergoing vitreoretinal surgery. METHODS: The procedures included were pars plana vitrectomy and scleral buckling. We developed a uniform classification to grade the bleeding severity. Bleeding was graded on an ordinal scale ranging from 0 to 5. Immediately after surgery and 1 day later, the incidence and the severity of bleeding events was documented on a standardized form. A grade of 3 or more was defined as severe bleeding. Furthermore, the influence of known systemic disorders before surgery, the type of anesthesia, type of surgical procedure, intraoperative blood pressure, and the use or change of antiplatelet or anticoagulant agents on intraoperative bleeding was analyzed. MAIN OUTCOME MEASURES: Incidence and risk factors for severe intraoperative bleeding events. RESULTS: Data from 374 eyes undergoing vitreoretinal procedures were included in our study (mean age, 67.6 ± 12.9 years). A severe intraoperative bleeding event was observed in 15 eyes (4%). We found that concomitant diseases such as diabetes mellitus and carotid artery stenosis, the presence of diabetic retinopathy, younger age, and scleral buckling combined with a transscleral puncture were associated significantly with severe bleeding events. By contrast, use of antiplatelet or anticoagulant agents, or both, had no significant influence on severe intraoperative bleeding events. CONCLUSIONS: Although external manipulations during buckling surgery (e.g., drainage of subretinal fluid) and concomitant diseases such as diabetes mellitus and carotid artery stenosis influences the risk of severe intraoperative bleeding events, we did not detect an increased risk related to coexisting antiplatelet or anticoagulant medication use, or both.


Subject(s)
Anticoagulants/adverse effects , Blood Loss, Surgical/statistics & numerical data , Cardiovascular Diseases/drug therapy , Eye Hemorrhage/epidemiology , Platelet Aggregation Inhibitors/adverse effects , Retinal Diseases/surgery , Vitreoretinal Surgery/adverse effects , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/complications , Eye Hemorrhage/chemically induced , Eye Hemorrhage/diagnosis , Follow-Up Studies , Germany/epidemiology , Humans , Incidence , Middle Aged , Prognosis , Prospective Studies , Retinal Diseases/complications , Risk Assessment , Risk Factors , Severity of Illness Index , Young Adult
3.
J Intensive Care Med ; 21(1): 27-39, 2006.
Article in English | MEDLINE | ID: mdl-16698742

ABSTRACT

The objective was to evaluate the efficacy and safety of recombinant activated factor VII in patients with massive bleeding. Forty-five patients with severe massive hemorrhage requiring>or= 14 transfusion units of packed red blood cells received recombinant activated factor VII. Postdrug blood loss and transfusion requirements were assessed, and mortality was compared with predicted outcomes. Blood loss was markedly reduced in 40 of 43 (93.0%) patients, and transfusion requirements decreased after recombinant activated factor VII administration. Mortality rate in trauma patients who had massive hemorrhage was significantly reduced compared with predictions using scoring systems. This may be associated with the use of recombinant activated factor VII. This study failed to demonstrate an improvement in surgical patients. The absence of concurrent controls prevents definitive conclusions regarding actual safety or efficacy of recombinant activated factor VII.


Subject(s)
Blood Loss, Surgical/prevention & control , Factor VIIa/therapeutic use , Hemorrhage/drug therapy , Hemorrhage/etiology , Wounds and Injuries/complications , Adolescent , Adult , Aged , Canada , Dose-Response Relationship, Drug , Europe , Female , Hemostatic Techniques , Humans , Injury Severity Score , Male , Middle Aged , Registries , Risk Assessment/methods , Survival Analysis , Treatment Outcome , Wounds and Injuries/classification
4.
Crit Care Med ; 33(10): 2241-6, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16215377

ABSTRACT

OBJECTIVE: Analysis of safety and efficacy of recombinant activated factor VII (rFVIIa) used as the last resort for refractory bleeding after cardiac surgery. DESIGN: Retrospective cohort analysis and matched pairs analysis with historic controls were performed. In the rFVIIa group, which also received conventional hemostatic therapy, data were collected for a median of 14 hrs from admission to the intensive care unit (ICU) to the administration of rFVIIa and for the following 24 hrs. In the control group, which received only conventional hemostatic therapy, data were collected for 14 and then for 24 hrs after admission to the ICU. SETTING: University hospital. PATIENTS: Twenty-four patients matched with historic controls. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: No thromboembolic complications were observed in the rFVIIa group. Blood loss and transfusion requirements were significantly reduced in the period after the administration of rFVIIa. However, in the 24-hr period after rFVIIa administration, blood loss (p = .140) and transfusion of packed red blood cells (p = .442) and fresh frozen plasma (p = .063) were not different between the rFVIIa and control groups. Platelet concentrates (p = .004) were transfused less in the control group. Mortality and 6-month survival rates were not different between the groups. CONCLUSIONS: When used as a last resort, rFVIIa was safe but not incrementally efficacious over conventional hemostatic therapy.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Factor VII/therapeutic use , Hemostatics/therapeutic use , Postoperative Hemorrhage/drug therapy , Postoperative Hemorrhage/etiology , Aged , Aged, 80 and over , Blood Transfusion , Cohort Studies , Factor VIIa , Female , Humans , Male , Middle Aged , Postoperative Hemorrhage/mortality , Recombinant Proteins/therapeutic use , Retrospective Studies , Survival Rate , Treatment Outcome
5.
Drugs R D ; 5(2): 63-71, 2004.
Article in English | MEDLINE | ID: mdl-15293865

ABSTRACT

OBJECTIVE: To investigate the effect of the red vine leaf extract AS 195 on cutaneous microvascular blood flow, transcutaneous oxygen pressure (tcpO2), and leg oedema in patients with chronic venous insufficiency (CVI). DESIGN AND PATIENTS: The study was a randomised, double-blind, placebo-controlled, crossover trial for which 129 men and women, aged > or =18 years, with CVI stage I or II were screened. Seventy-one fulfilled the inclusion criteria and were randomised. INTERVENTIONS: A total of 71 patients were divided into two groups. The first group (n = 36) received AS 195 360mg once daily during a first 6-week treatment period, followed by a 4-week placebo washout period and then placebo during the second 6-week treatment period. The second group (n = 35) started with placebo and received AS 195 360mg after the placebo washout. The cutaneous microvascular blood flow in the malleolar region was measured using a newly developed laser Doppler device. TcpO2 was measured using a solid-state electrode. RESULTS: After 6 weeks, patients in the AS 195 group had increased microvascular blood flow values (+241.8 +/- 18.7 arbitrary units [AU] versus a decrease of -41.0 +/- 18.7AU in the placebo group; p < 0.0001). Oxygen increased to 1.35 +/- 0.97mm Hg (placebo: decrease of -7.27 +/- 0.97mm Hg; p < 0.0001). After 6 weeks of treatment the leg circumference was decreased (ankle level: by -0.39 +/- 0.09cm versus +0.29 +/- 0.09cm; p < 0.0001; calf level: by -0.54 +/- 0.05cm versus +0.14 +/- 0.05cm; p < 0.0001). CONCLUSION: The administration of AS 195 improved objective symptoms of CVI and may prevent CVI deterioration.


Subject(s)
Flavonoids/therapeutic use , Phytotherapy , Skin/blood supply , Venous Insufficiency/drug therapy , Adult , Aged , Blood Gas Monitoring, Transcutaneous , Chronic Disease , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Microcirculation/drug effects , Middle Aged , Plant Extracts/therapeutic use , Plant Leaves , Venous Insufficiency/physiopathology , Vitis
6.
Clin Appl Thromb Hemost ; 10(3): 195-204, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15247976

ABSTRACT

The findings of a large prospective study designed to identify primary and/or secondary hemostatic disorders before surgical interventions are presented. A total of 5649 unselected adult patients were enrolled to identify impaired hemostasis before surgical interventions. Each patient was asked to answer a standardized questionnaire concerning bleeding history. Activated partial thromboplastin time (aPTT), prothrombin time (PT), and platelet counts (PC) including PFA-100 (platelet function analyzer): collagen-epinephrine (C/E), and collagen-ADP (C/ADP) were routinely done in all patients. Additional tests, bleeding time (BT), and von Willebrand factor (vWF: Ag) were performed only in patients with a positive bleeding history and/or evidence of impaired hemostasis; e.g., drug ingestion. The bleeding history was negative in 5021 patients (88.8%) but positive in the remaining 628 (11.2%). Impaired hemostasis could be verified only in 256 (40.8%) of these patients. The vast majority were identified with PFA-100: C/E (n=250; 97.7%). The other six patients with impaired hemostasis were identifiable solely based on the PT (n=2), PFA-100: C/ADP (n=2), and vWF: Ag (n=2). The PFA-100: C/ADP detected 199 patients (77.7%). The only abnormality found among patients with a negative bleeding history was a prolonged aPTT due to lupus anticoagulant in nine patients (0.2%). The sensitivity of the PFA-100: collagen-epinephrine was the highest (90.8%) in comparison to the other screening tests (BT, aPTT, PT, vWF: Ag). The positive predictive value of the PFA-100: collagen-epinephrine was high (81.8%), but the negative predictive value was higher (93.4%). The use of a standardized questionnaire and, if indicated, the PFA-100: C/E and/or other specific tests not only ensure the detection of impaired hemostasis in almost every case but also a significant reduction of the cost.


Subject(s)
Blood Coagulation Disorders/diagnosis , Preoperative Care/methods , Adolescent , Adult , Aged , Aged, 80 and over , Antigens/analysis , Blood Coagulation/drug effects , Blood Coagulation Disorders/blood , Blood Coagulation Disorders/epidemiology , Blood Coagulation Disorders/genetics , Blood Coagulation Tests , Collagen/pharmacology , Elective Surgical Procedures , Epinephrine/pharmacology , Female , Fibrinogen , Humans , Male , Mass Screening , Medical Records , Middle Aged , Partial Thromboplastin Time , Platelet Activation/drug effects , Platelet Function Tests/instrumentation , Predictive Value of Tests , Prevalence , Prospective Studies , ROC Curve , Sensitivity and Specificity , Surveys and Questionnaires , Thrombophilia/blood , Thrombophilia/diagnosis , Thrombophilia/epidemiology , von Willebrand Factor/immunology
7.
Clin Appl Thromb Hemost ; 10(2): 155-66, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15094936

ABSTRACT

In a prospective study, 254 of 5649 unselected patients scheduled for surgery at our hospital were identified preoperatively as having either acquired (n=182) or inherited (n=72) impaired primary hemostasis (platelet dysfunction including von Willebrand disease). All patients were initially pretreated with desmopressin (DDAVP). Response to DDAVP or subsequent treatment(s) was defined as correction of any one of the abnormal PFA-100 platelet function tests. The non-responders were additionally treated with tranexamic acid or aprotinin; those with von Willebrand disease (vWD) received factor VIII concentrates with von Willebrand factor (vWF). Those still unresponsive to therapy received conjugated estrogens and, as a last attempt, a platelet transfusion. The administration of DDAVP led to a correction of platelet dysfunction in 229 of the 254 patients treated (90.2%). Tranexamic acid was effective in 12 of 16, aprotinin in 3 of 5, and factor VIII concentrates with vWF in all 4 patients with unresponsive to DDAVP. The remaining 6 patients were pretreated with conjugated estrogens, and 2 of these patients were additionally treated with platelet transfusion. The frequency of blood transfusion was lower, but not statistically significant (9.4% vs. 12.2%: p = 0.202) in preoperatively treated patients with impaired hemostasis than in patients without impaired hemostasis. In a retrospective group, the frequency of blood transfusion was statistically significant higher (89.3% vs. 11.3%: p < 0.001) in patients without preoperative correction of impaired hemostasis than in patients without impaired hemostasis. Preoperative correction of impaired primary hemostasis is possible in nearly all patients affected, and results in a reduction of homologous blood transfusions.


Subject(s)
Blood Platelet Disorders/therapy , Hemostasis , Preoperative Care , Adolescent , Adult , Aged , Aged, 80 and over , Bleeding Time , Blood Platelet Disorders/drug therapy , Blood Platelet Disorders/physiopathology , Blood Platelet Disorders/surgery , Blood Platelets/drug effects , Blood Platelets/metabolism , Blood Transfusion , Deamino Arginine Vasopressin/pharmacology , Female , Humans , Male , Middle Aged , von Willebrand Diseases/drug therapy , von Willebrand Diseases/physiopathology , von Willebrand Diseases/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...